Skip to main content

Table 4 Secondary outcomes expressed as weighted mean differences between intervention and control groups

From: Results from the CLUES study: a cluster randomized trial for the evaluation of cardiovascular guideline implementation in primary care in Spain

  WMD 95% CI p
Diabetes guideline
 HbA1c < 7% −3.05 −9.16 to 3.07 0.320
 Annual general laboratory testing 3.83 −30.74 to 38.41 0.824
 Annual coronary risk assessment 28.16 7.22 to 49.08 0.010
 Annual foot examination 13.08 −5.30 to 31.45 0.158
 Blood pressure < 140/80 mmHg −2.52 −12.10 to 7.06 0.598
 Metformin/All new antidiabetic monotherapy 17.83 −3.22 to 38.88 0.095
Hypertension guideline
 Blood pressure < 140/90 mmHg 3.76 −4.14 to 11.66 0.342
 Annual coronary risk assessment 27.55 7.38 to 47.71 0.009
 Diuretics/All new antihypertensive monotherapy 20.58 6.44 a 34.73 0.005
 Beta blockers/All new antihypertensive monotherapy −8.24 −21.77 to 5.29 0.226
 ARB-II/All new antihypertensive monotherapy 11.32 −10.16 to 32.81 0.293
Dyslipidemia guideline
 New statin treatments with previous coronary risk assessment 23.09 7.26 to 38.92 0.005
 New statin treatments in low-risk women −3.08 −5.20 to −0.94 0.006
 Patients with coronary heart disease receiving statin treatment 13.47 −14.36 to 41.30 0.334
  1. ARB II angiotensin II receptor blockers, CI Confidence Interval, p p-value derived by Student’s t-test, WMD weighted mean difference